Cargando…
Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment
BACKGROUND: Due to the sensitivity and potential embarrassment of discussing erectile dysfunction (ED) in person, men are seeking treatment online. AIMS: We sought to compare offerings of direct-to-consumer (DTC) platforms for ED treatment with respect to consultation, pricing, services, and privacy...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397420/ https://www.ncbi.nlm.nih.gov/pubmed/37547870 http://dx.doi.org/10.1093/sexmed/qfad038 |
_version_ | 1785083908880072704 |
---|---|
author | Brink, Sarah M Iarajuli, Teona Shin, David |
author_facet | Brink, Sarah M Iarajuli, Teona Shin, David |
author_sort | Brink, Sarah M |
collection | PubMed |
description | BACKGROUND: Due to the sensitivity and potential embarrassment of discussing erectile dysfunction (ED) in person, men are seeking treatment online. AIMS: We sought to compare offerings of direct-to-consumer (DTC) platforms for ED treatment with respect to consultation, pricing, services, and privacy policy. METHODS: Google was queried to identify DTC platforms offering ED treatment with the keywords: “telehealth erectile dysfunction,” “telemedicine erectile dysfunction,” and “online erectile dysfunction.” Inclusion criteria were as follows: serving a majority of U.S. states, existing online only, providing both the consultation and prescription for phosphodiesterase type 5 inhibitors, and delivering the prescription to the patient. RESULTS: Fifteen DTC platforms met criteria. Ten provided free consultations; 4 bundled the consultation fee with the first month of the prescription, with 1 of these functioning as a subscription service. Fourteen (93%) relied on online intake forms and 10 (67%) advertised review by the prescriber within 2 business days. Only 4 (27%) platforms explicitly advertised physician-only consults. Direct contact with the prescriber would only occur if needed or if required by state law at 8 (53%) platforms. Purchasing sildenafil and tadalafil was advertised on all platforms. Minimum prices of sildenafil ranged from $0.50 to $35/pill (mean $5.16/pill, median $2.65/pill); tadalafil ranged from $0.50 to $9.80/pill (mean $4.70/pill, median $3.21/pill). In addition to ED therapy, 13 (86%) platforms offered treatment for other men’s health issues. All platforms included a website privacy policy, but only 10 (67%) mentioned Health Insurance Portability and Accountability Act compliance, with 2 of these claiming to not be covered entities. CONCLUSION: Although DTC platforms are transparent with phosphodiesterase type 5 inhibitor medication and subscription pricing information, few offer direct contact with a physician to further discuss issues related to ED after completion of the online intake form. For comprehensive evaluation of ED in Health Insurance Portability and Accountability Act–compliant settings, in-person or telemedicine visits should be arranged with men’s physicians. |
format | Online Article Text |
id | pubmed-10397420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103974202023-08-04 Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment Brink, Sarah M Iarajuli, Teona Shin, David Sex Med Brief Report BACKGROUND: Due to the sensitivity and potential embarrassment of discussing erectile dysfunction (ED) in person, men are seeking treatment online. AIMS: We sought to compare offerings of direct-to-consumer (DTC) platforms for ED treatment with respect to consultation, pricing, services, and privacy policy. METHODS: Google was queried to identify DTC platforms offering ED treatment with the keywords: “telehealth erectile dysfunction,” “telemedicine erectile dysfunction,” and “online erectile dysfunction.” Inclusion criteria were as follows: serving a majority of U.S. states, existing online only, providing both the consultation and prescription for phosphodiesterase type 5 inhibitors, and delivering the prescription to the patient. RESULTS: Fifteen DTC platforms met criteria. Ten provided free consultations; 4 bundled the consultation fee with the first month of the prescription, with 1 of these functioning as a subscription service. Fourteen (93%) relied on online intake forms and 10 (67%) advertised review by the prescriber within 2 business days. Only 4 (27%) platforms explicitly advertised physician-only consults. Direct contact with the prescriber would only occur if needed or if required by state law at 8 (53%) platforms. Purchasing sildenafil and tadalafil was advertised on all platforms. Minimum prices of sildenafil ranged from $0.50 to $35/pill (mean $5.16/pill, median $2.65/pill); tadalafil ranged from $0.50 to $9.80/pill (mean $4.70/pill, median $3.21/pill). In addition to ED therapy, 13 (86%) platforms offered treatment for other men’s health issues. All platforms included a website privacy policy, but only 10 (67%) mentioned Health Insurance Portability and Accountability Act compliance, with 2 of these claiming to not be covered entities. CONCLUSION: Although DTC platforms are transparent with phosphodiesterase type 5 inhibitor medication and subscription pricing information, few offer direct contact with a physician to further discuss issues related to ED after completion of the online intake form. For comprehensive evaluation of ED in Health Insurance Portability and Accountability Act–compliant settings, in-person or telemedicine visits should be arranged with men’s physicians. Oxford University Press 2023-08-02 /pmc/articles/PMC10397420/ /pubmed/37547870 http://dx.doi.org/10.1093/sexmed/qfad038 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Brink, Sarah M Iarajuli, Teona Shin, David Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
title | Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
title_full | Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
title_fullStr | Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
title_full_unstemmed | Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
title_short | Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
title_sort | characteristics of direct-to-consumer platforms offering erectile dysfunction treatment |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397420/ https://www.ncbi.nlm.nih.gov/pubmed/37547870 http://dx.doi.org/10.1093/sexmed/qfad038 |
work_keys_str_mv | AT brinksarahm characteristicsofdirecttoconsumerplatformsofferingerectiledysfunctiontreatment AT iarajuliteona characteristicsofdirecttoconsumerplatformsofferingerectiledysfunctiontreatment AT shindavid characteristicsofdirecttoconsumerplatformsofferingerectiledysfunctiontreatment |